249 results on '"Chao, Jingdong"'
Search Results
2. Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis
3. Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)
4. Content validity of a newly developed observer-reported measure for pediatric asthma in children aged 2–5 years
5. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma
6. Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
7. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
8. Dupilumab Improves Treatment Satisfaction and Health-Related Quality of Life in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD
9. Dupilumab Improves Disease Control and Patient-Reported Outcomes in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD
10. Dupilumab Decreases Concomitant Therapy use in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD
11. Efficacy of dupilumab in moderate and severe atopic dermatitis
12. Increased Risk of Venous Thromboembolic Events With Corticosteroid vs Biologic Therapy for Inflammatory Bowel Disease
13. Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study
14. Adalimumab Induces Deep Remission in Patients With Crohn's Disease
15. Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease
16. Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study
17. Response to the correspondence: “Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma”
18. Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020)
19. Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
20. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
21. Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab
22. Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab
23. WITHDRAWN: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma
24. Letter: is unrealised adult height resulting from paediatric Crohn’s disease associated with a potential reduction in lifetime earnings?
25. Response to the correspondence: “Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma”
26. Mo1217 QUALITATIVE PATIENT INTERVIEWS TO ASSESS CONTENT VALIDITY OF THE MODIFIED DYSPHAGIA SYMPTOM QUESTIONNAIRE
27. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system
28. Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis
29. Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use.
30. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis
31. Mo1892 The Identification of Vedolizumab Claims before J-Code Assignment to Assess Immunomodulator Combination Therapy With Vedolizumab, Adalimumab, and Infliximab
32. Mo1097 Adalimumab Improves Treatment Satisfaction With Medication and Work Productivity Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From INSPIRADA
33. Tu1905 Assessment of the Real-World Safety Profile of Vedolizumab Using the United States Food and Drug Administration Adverse Event Reporting System (FAERS)
34. Mo1090 The Costs of Care for Patients With Ulcerative Colitis: Effect of Adalimumab on Health Care Resources Utilisation in Clinical Practice From INSPIRADA
35. Mo1096 Effect of Adalimumab on Clinical Outcomes and Health-Related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From INSPIRADA
36. Mo1864 Current Trends in the Quality of Care of Inflammatory Bowel Disease in the United States
37. Tu1933 Fecal Calprotectin Improves the Predictive Power of 3 Practical Indices for Mucosal Healing Among Patients With Crohn's Disease: Results From PREDICT
38. Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis
39. Su1239 Underestimation of Ulcerative Colitis Disease Severity: What Affects the Clinical Assessment? Results From a Case Study Survey
40. Tu1305 Analysis of Outcomes After Non-Medical Switching of Anti-Tumor Necrosis Factor Agents
41. Tu1306 Clinical Outcomes Associated With Switching or Discontinuation of Anti-TNF Inhibitors for Non-Medical Reasons
42. 149 The Indirect Costs and Family Burden of Pediatric Crohn's Disease in the United States
43. Tu1336 Cost Per Remitter Associated With Biologic Therapies for Crohn's Disease
44. Sa1258 Comparison of Real-World Outcomes of Adalimumab (ADA) and Infliximab (IFX) for Patients With Ulcerative Colitis (UC) in the United States
45. Tu1256 Comparison of Ulcerative Colitis With Crohn's Disease From the Perspective of Patient Burden
46. Sa1205 Association Between Disease Activity and Depression Among Patients With Moderate to Severe Crohn's Disease
47. Mo1232 Indirect Comparison of Adalimumab, Infliximab, and Golimumab in Ulcerative Colitis: Cost Per Remitter Analysis
48. Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis
49. Su1184 Impact of Ulcerative Colitis on Patient Quality of Life in a Real-World Clinical Setting
50. Mo1254 Reduction in Colectomy- and Health Care-Related Costs in Ulcerative Colitis Patients Treated With Adalimumab Compared With Standard Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.